PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,771,401 | -39.9% | 1,617,300 | -17.0% | 0.68% | -30.8% |
| Q2 2023 | $27,919,704 | +90.9% | 1,949,700 | -4.8% | 0.98% | +100.6% |
| Q1 2023 | $14,627,004 | -31.4% | 2,048,600 | +7.8% | 0.49% | +5.2% |
| Q4 2022 | $21,318,000 | +0.9% | 1,900,000 | -0.4% | 0.46% | +7.4% |
| Q3 2022 | $21,127,000 | +30.4% | 1,906,800 | -0.7% | 0.43% | +15.6% |
| Q2 2022 | $16,203,000 | -38.8% | 1,919,800 | -1.3% | 0.37% | -32.5% |
| Q1 2022 | $26,485,000 | -29.0% | 1,946,000 | +2.6% | 0.55% | -30.3% |
| Q4 2021 | $37,294,000 | +636.2% | 1,896,000 | +1143.3% | 0.79% | +382.3% |
| Q4 2020 | $5,066,000 | – | 152,500 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |